USP5 Data Analysis

HGNC Gene Name
ubiquitin specific peptidase 5
HGNC Gene Symbol
USP5
Identifiers
hgnc:12628 NCBIGene:8078 uniprot:P45974
Orthologs
mgi:1347343 rgd:1308438
INDRA Statements
deubiquitinations all statements
Pathway Commons
Search for USP5
Number of Papers
118 retrieved on 2022-05-22

DepMap Analysis

The Dependency Map (DepMap) is a genome-wide pooled CRISPR-Cas9 knockout proliferation screen conducted in more than 700 cancer cell lines spanning many different tumor lineages. Each cell line in the DepMap contains a unique barcode, and each gene knockout is assigned a “dependency score” on a per cell-line basis which quantifies the rate of CRISPR-Cas9 guide drop. It has been found that proteins with similar DepMap scores across cell lines, a phenomenon known as co-dependent genes, have closely related biological functions. This can include activity in the same or parallel pathways or membership in the same protein complex or the same pathway.

We identified the strongest seven co-dependent genes (“Symbol”) for DUBs and ran GO enrichment analysis. We used Biogrid, IntAct, and Pathway Commons PPIDs, and the NURSA protein-protein interaction databases (PPIDs) to determine whether co-dependent genes interact with one another. The “Evidence” column contains the PPIDs in which the interaction appears as well as whether there is support for the association by an INDRA statement. As another approach to identify potential interactors, we looked at proteomics data from the Broad Institute's Cancer Cell Line Encyclopedia (CCLE) for proteins whose expression across ~375 cell lines strongly correlated with the abundance of each DUB; it has previously been observed that proteins in the same complex are frequently significantly co-expressed. The correlations and associated p-values in the CCLE proteomics dataset are provided. And, we determined whether co-dependent genes yield similar transcriptomic signatures in the Broad Institute's Connectivity Map (CMap). A CMap score greater than 90 is considered significantly similar.

DepMap Correlations

Symbol Name DepMap Correlation Evidence CCLE Correlation CCLE Z-score CCLE p-value (adj) CCLE Significant CMAP Score CMAP Type
HSPE1 heat shock protein family E (Hsp10) member 1 0.401 -0.04 -0.28 6.18e-01
RAN RAN, member RAS oncogene family 0.397 0.50 2.64 1.05e-22
PSMD7 proteasome 26S subunit, non-ATPase 7 0.392 INDRA (1) Reactome (4) 0.29 1.51 9.79e-08
CHEK1 checkpoint kinase 1 0.391 0.38 2.01 1.11e-12
SARS1 seryl-tRNA synthetase 1 0.391 Reactome (1) 0.47 2.51 2.51e-20
ANAPC4 anaphase promoting complex subunit 4 0.384 -0.03 -0.28 6.23e-01
NEDD1 NEDD1 gamma-tubulin ring complex targeting factor 0.373 0.26 1.32 3.87e-06

Dependency GO Term Enrichment

Gene set enrichment analysis was done on the genes correlated with USP5using the terms from Gene Ontology and gene sets derived from the Gene Ontology Annotations database via MSigDB.

Using the biological processes and other Gene Ontology terms from well characterized DUBs as a positive control, several gene set enrichment analyses were considered. Threshold-less methods like GSEA had relatively poor results. Over-representation analysis with a threshold of of the top 7 highest absolute value Dependency Map correlations yielded the best results and is reported below.

GO Identifier GO Name GO Type p-value p-value (adj.) q-value
GO:1901987 regulation of cell cycle phase transition Biological Process 1.31e-05 3.93e-03 1.97e-03
GO:1902749 regulation of cell cycle G2/M phase transition Biological Process 4.86e-05 1.46e-02 3.65e-03
GO:0044839 cell cycle G2/M phase transition Biological Process 9.46e-05 2.84e-02 4.09e-03
GO:0140014 mitotic nuclear division Biological Process 1.09e-04 3.26e-02 4.09e-03

Transcriptomics

The following table shows the significantly differentially expressed genes after knocking out USP5 using CRISPR-Cas9.

Knockout Differential Expression

Symbol Name log2-fold-change p-value p-value (adj.)
UBC ubiquitin C 3.77e-01 1.14e-09 2.51e-05

Gene Set Enrichment Analysis

There were too few differentially expressed genes to run a meaningful GSEA.

Literature Mining

INDRA was used to automatically assemble known mechanisms related to USP5 from literature and knowledge bases. The first section shows only DUB activity and the second shows all other results.

Deubiquitinase Activity

psp cbn pc bel_lc signor biogrid lincs_drug tas hprd trrust ctd vhn pe drugbank omnipath conib crog dgi | rlimsp isi tees geneways eidos trips medscan sparser reach
USP5 leads to the deubiquitination of MAF. 4 / 4
| 3

reach
Because USP5, as a deubiquitinase of c-Maf, binds to and suppresses c-Maf polyubiquitination, we sought to determine whether mebendazole could interfere with the association of c-Maf and USP5.

ubibrowser
Consistent with the high level of c-Maf protein in MM cells, USP5 was also highly expressed.

reach
C-Maf ubiquitination can be reversed by the deubiquitinase USP5 because USP5 prevents c-Maf from polyubiquitination and degradation [XREF_BIBR].

reach
C-Maf ubiquitination can be reversed by the deubiquitinase USP5 because USP5 prevents c-Maf from polyubiquitination and degradation [8].
USP5 leads to the deubiquitination of SNAI2. 3 / 3
| 2

reach
Formononetin targets USP5 to inhibit the deubiquitination of SLUG.

reach
Collectively, these results indicated that USP5 promotes SLUG stabilization by deubiquitinating SLUG.

ubibrowser
USP5 interacts with and stabilizes SLUG to regulate its abundance through USP5 deubiquitination activities in epithelial-mesenchymal transition (EMT) of hepatocellular carcinoma (HCC).
USP5 leads to the deubiquitination of CACNA1H. 2 / 2
| 1

reach
Knockdown of USP5 via shRNA increases Cav3.2 ubiquitination, decreases Cav3.2 protein levels, and reduces Cav3.2 whole-cell currents.

ubibrowser
Review
USP5 deubiquitinates TP53. 2 / 2
| 1

ubibrowser
Review

reach
USP5 deubiquitinates p53 [XREF_BIBR], while USP2a acts on Mdm2 [XREF_BIBR], and differences in the levels of the two proteases can affect p53 levels.
Modified USP5 leads to the deubiquitination of FOXM1. 1 / 1
| 1

reach
Overexpression of USP5 reduces the endogenous ubiquitination of FoxM1 and increases FoxM1 expression [25].
USP5 deubiquitinates MAFA. 1 / 1
| 1

reach
Notably, MafA and MafB are also members of the c-Maf family, however, USP5 failed to deubiquitinate MafA, suggesting its substrate specificity.
USP5 deubiquitinates CTNNB1. 1 / 1
| 1

reach
Mechanistically, we found that USP5 deubiquitinated beta-catenin, prevented ubiquitination mediated beta-catenin degradation and promoted beta-catenin nuclear accumulation, leading to the activation of Wnt and beta-catenin signal pathway in NSCLC cells.
USP5 deubiquitinates STING1. 1 / 1
|

ubibrowser
In addition, the ubiquitination of STING was impaired by USP5, USP13, and USP22.
USP5 deubiquitinates CD274. 1 / 1
| 1

reach
USP5 directly interacted with PD-L1 and deubiquitinated PD-L1, therefore enhances PD-L1 protein stability.
USP5 leads to the deubiquitination of Proteasome. 1 / 1
| 1

reach
Interestingly, we also discovered that the human gene encoding the ubiquitin specific peptidase 5 (USP5), which is known to promote cellular deubiquitination and ubiquitin and proteasome dependent proteolysis, was a direct transcriptional target for miR-125a to repress.
USP5 desumoylates AXIN1. 1 / 1
| 1

sparser
In the present manuscript, we demonstrate that SENP7S is a functional SUMO isopeptidase that deSUMOylates β-catenin and Axin1.
USP5 deubiquitinates TUFM. 1 / 1
| 1

reach
USP5 deubiquitinated TUFM and increased its level in CRC cells.
USP5 desumoylates CTNNB1. 1 / 1
| 1

sparser
In the present manuscript, we demonstrate that SENP7S is a functional SUMO isopeptidase that deSUMOylates β-catenin and Axin1.
USP5 leads to the deubiquitination of HDAC2. 1 / 1
| 1

reach
Moreover, USP5 interacted with HDAC2, and disruption of USP5 enhanced the ubiquitination of HDAC2.
USP5 deubiquitinates WT1. 1 / 1
| 1

reach
We further identified that USP5 deubiquitinated WT1 and stabilized its expression.
USP5 deubiquitinates FOXM1. 1 / 1
|

ubibrowser
Review
USP5 deubiquitinates MAFB. 1 / 1
|

ubibrowser
USP5 was found to interact with c-Maf and prevented it from degradation by decreasing its polyubiquitination level| Notably, MafA and MafB are also members of the c-Maf family, however, USP5 failed to deubiquitinate MafA, suggesting its substrate specificity.
USP5 desumoylates USP5. 1 / 1
| 1

reach
We acknowledge the caveat that a USP5 construct with a point mutation that prevents SUMOylation is not strictly equivalent to deSUMOylation of USP5.

Other Statements

psp cbn pc bel_lc signor biogrid lincs_drug tas hprd trrust ctd vhn pe drugbank omnipath conib crog dgi | rlimsp isi tees geneways eidos trips medscan sparser reach
Nitric oxide affects USP5
| 21
Nitric oxide inhibits USP5.
| 11
| 11

reach
NO inhibits isopeptidase T activity in a concentration dependent manner.

reach
Furthermore, it is possible that NO may prevent protein breakdown by affecting the activity of isopeptidase T through S nitrosylation of active site cysteines.

reach
We show, for the first time, that NO inhibits isopeptidase T activity in the vasculature, most likely by S nitrosylation of a critical cysteine residue, a common mechanism by which NO regulates the activity of cysteine proteases.

reach
To determine if NO inhibits isopeptidase T activity via modification of cysteine thiol groups, DTT (5 mmol/L) was added to the activity assay before SNAP (1000 mumol/L).

reach
This correlation between the effect of NO on isopeptidase T activity and the presence of S nitrosylated isopeptidase T is further strengthened by evidence that NO inhibits isopeptidase T activity in a concentration dependent fashion in vitro.

reach
As NO can cause S nitrosylation of active-site cysteines, we hypothesize that NO inhibits isopeptidase T activity through S nitrosylation.

reach
NO inhibited recombinant isopeptidase T activity by 82.8% (t = 60 minutes, P <.001 vs control).

reach
We demonstrate here that NO inhibits the activity, but not levels, of isopeptidase T in VSMC in vitro, while decreasing its levels and increasing ubiquitinated proteins in the vasculature in vivo.

reach
We expect that these experiments would indicate that NO decreases isopeptidase T activity in vivo, which would lead to ubiquitin-proteasome pathway inhibition as a result of accumulation of proteins with unprocessed K48 linked polyubiquitin chains.

reach
Dithiothreitol and glutathione (5 mmol/L) both significantly reversed NO mediated inhibition of isopeptidase T activity (P <.001).
Nitric oxide decreases the amount of USP5.
| 4
Nitric oxide decreases the amount of USP5. 4 / 5
| 4

reach
Although NO decreased the overall levels of isopeptidase T throughout the arterial wall at both time points after injury, the most prominent decrease was seen at 14 days.

reach
We provide evidence that, although administration of NO in vitro had no effect on isopeptidase T levels or intracellular localization in VSMC, external administration of NO in vivo in a carotid artery model of neointimal hyperplasia decreased isopeptidase T levels, while increasing levels of ubiquitinated proteins.

reach
Finally, we show that periadventitial administration of NO decreases levels of isopeptidase T in an animal model of neointimal hyperplasia, which correlates with increased ubiquitinated protein levels.

reach
Isopeptidase T was located mostly in the cytoplasm (XREF_FIG), and addition of NO did not affect intracellular localization of isopeptidase T. NO decreases isopeptidase T levels in vivo.
Nitric oxide increases the amount of USP5.
| 3
Nitric oxide increases the amount of USP5. 3 / 4
| 3

reach
Local administration of NO may prevent neointimal hyperplasia by inhibiting isopeptidase T levels and activity in the vasculature, thereby inhibiting the 26S proteasome in VSMCs.

reach
Nitric oxide may inhibit neointimal hyperplasia by decreasing isopeptidase T levels and activity in the vasculature.

reach
NO caused a time dependent increase in S nitrosylated isopeptidase T levels in VSMCs, which was reversible with dithiothreitol, indicating that isopeptidase T undergoes reversible S nitrosylation on exposure to NO in vitro.
Nitric oxide activates USP5.
| 3
| 3

reach
NO causes S nitrosylation of isopeptidase T in a time dependent manner.

reach
We conclude that local administration of NO may prevent the formation of neointimal hyperplasia by inhibiting isopeptidase T activity via S nitrosylation, resulting in accumulation of unanchored polyubiquitin chains and further inhibiting the 26S proteasome.

reach
Local administration of NO may prevent neointimal hyperplasia by targeting isopeptidase T and inhibiting the 26S proteasome.
Mebendazole affects USP5
| 5 18
Mebendazole inhibits USP5.
| 5 9
| 5 9

eidos
Mebendazole downregulated USP5 expression and disrupted the interaction between USP5 and c-Maf , thus leading to increased levels of c-Maf ubiquitination and subsequent c-Maf degradation .

reach
Mebendazole inhibits the USP5 and c-Maf axis and induces c-Maf degradation via the ubiquitin-proteasome pathway.

reach
From this screen, we identified mebendazole, an agent widely used for the treatment of human gastrointestinal parasitic infections [9], selectively induces MM cell apoptosis by targeting USP5 and c-Maf signaling.Cell culture Human embryonic kidney cells (HEK293T) were maintained in Dulbecco 's modified Eagle 's medium.

eidos
In the above studies , mebendazole was demonstrated to downregulate USP5 expression and disrupt the interaction between USP5 and c-Maf .

reach
The above studies provided strong evidence that mebendazole inhibits the USP5 and c-Maf axis and induces MM cell apoptosis.

reach
The above results demonstrated that mebendazole suppressed the USP5 and c-Maf axis and promoted c-Maf degradation; therefore, mebendazole might downregulate the transcriptional activity of c-Maf.

reach
The results showed that mebendazole decreased the USP5 content in the c-Maf immunoprecipitates in both exogenous and endogenous contexts, as shown in HEK293T and MM cells, respectively, suggesting that the interaction between USP5 and c-Maf was disrupted by mebendazole.

reach
Collectively, these results thus showed marked synergy between mebendazole and USP5 inhibitors or anti-MM drugs such as daunorubicin.Mebendazole delays the growth of human multiple myeloma xenografts in a nude mouse model The above studies provided strong evidence that mebendazole inhibits the USP5 and c-Maf axis and induces MM cell apoptosis.

reach
From this screen, we identified mebendazole, an agent widely used for the treatment of human gastrointestinal parasitic infections [XREF_BIBR], selectively induces MM cell apoptosis by targeting USP5 and c-Maf signaling.

reach
Mebendazole elicits potent antimyeloma activity by inhibiting the USP5 and c-Maf axis.
Mebendazole decreases the amount of USP5.
| 8
Mebendazole decreases the amount of USP5. 8 / 8
| 8

reach
Notably, we found that USP5 mRNA expression was also decreased by mebendazole, suggesting that mebendazole might suppress USP5 transcription.

reach
Mebendazole downregulated USP5 expression and disrupted the interaction between USP5 and c-Maf, thus leading to increased levels of c-Maf ubiquitination and subsequent c-Maf degradation.

reach
The mechanistic investigation showed that mebendazole not only prevents the interaction between USP5 and c-Maf but also suppresses USP5 transcription, thus inducing c-Maf proteasomal degradation.

reach
In the above studies, mebendazole was demonstrated to downregulate USP5 expression and disrupt the interaction between USP5 and c-Maf.

reach
The mechanistic investigation showed that mebendazole not only prevents the interaction between USP5 and c-Maf but also suppresses USP5 transcription, thus inducing c-Maf proteasomal degradation.Notably, mebendazole is cytotoxic to various cancer cells, including MM and leukemia cells, at higher concentrations (data not shown); however, it elicits selective anti-MM activity at low concentrations.

reach
Notably, we found that USP5 mRNA expression was also decreased by mebendazole, suggesting that mebendazole might suppress USP5 transcription.Because c-Maf turnover is processed via the proteasome, we sought to determine whether mebendazole induced c-Maf Fig. 2 Mebendazole inhibits USP5 expression and induces c-Maf degradation via the ubiquitin-proteasome pathway.

reach
The results showed that mebendazole downregulated the protein expression of both USP5 and c-Maf in both LP1 and RPMI-8226 cells.

reach
The results showed that mebendazole downregulated the protein expression of both USP5 Fig. 1 Identification of mebendazole as a promoter of c-Maf protein degradation.
Mebendazole activates USP5.
| 1
| 1

reach
HEK293T cells cotransfected with MARE.luci, c-Maf, and USP5 were treated with mebendazole for 24h, followed by a luciferase assay.

reach
These data indicated that USP5 effectively promoted EMT in NSCLC cells.

reach
Knockdown of USP5 inhibits SLUG deubiquitination and inhibits HCC cells proliferation, metastasis, and invasion, while overexpression of USP5 promotes SLUG stability and EMT in vitro and in vivo.

eidos
USP5 targets the transcription factor SLUG and then induces EMT in hepatocellular carcinoma cells ( Meng et al ., 2019 ) .

reach
These data indicated that USP5 promotes NSCLC metastasis by inducing EMT.

reach
In previous study, USP5 was found promoting EMT by stabilizing SLUG in hepatocellular carcinoma XREF_BIBR.

eidos
USP5 induces EMT and promotes migration and invasion in NSCLC cells .

reach
USP5 promotes EMT and metastasis in hepatocellular carcinoma.

eidos
USP5 promotes EMT and the invasion and migration of NSCLC cells .

eidos
USP5 promotes EMT through the regulation of GSK-3beta / beta-catenin .

reach
USP5 enhanced epithelial-mesenchymal transition (EMT)-induced metastasis by stabilizing SLUG.
USP5 increases the amount of epithelial to mesenchymal transition.
| 1

reach
Furthermore, USP5 overexpression significantly enhanced, whereas USP5 silencing significantly decreased the expression of EMT proteins and migration and invasion of NSCLC cells.
Ubiquitin affects USP5
| 2 1 12
Ubiquitin inhibits USP5.
| 2 1 7
| 2 1 6

reach
In addition, ubiquitin binds to and inhibits USP5.

reach
Also, USP5 has an asparagine at the corresponding position and is inhibited by ubiquitin.

eidos
In addition , ubiquitin binds to and inhibits USP5 .

reach
Also, USP5 has an asparagine at the corresponding position and is inhibited by ubiquitin.

sparser
In addition, ubiquitin binds to and inhibits USP5.

eidos
Also , USP5 has an asparagine at the corresponding position and is inhibited by ubiquitin .

reach
Kinetic studies on the inhibition of isopeptidase T by ubiquitin aldehyde.

reach
In contrast, Ub activated IPaseT is inhibited by Ub-H through a three-step process.

reach
In addition, ubiquitin binds to and inhibits USP5.
Ubiquitin-G76A inhibits USP5. 1 / 1
| 1

reach
As expected, Ub G76A -Ub did not label or inhibit OTULIN and USP5, but it also induced the dose dependent assembly of Ub chains that could be detected with anti-M1-polyUb antibody (XREF_FIG G).
Ubiquitin activates USP5.
| 5
| 5

reach
Both free and substrate conjugated polyubiquitin chains accumulate in leon mutants, suggesting that abnormal ubiquitin homeostasis caused tissue disorder and lethality in leon mutants.

reach
Recognition of the free C-terminus of the proximal ubiquitin in a poly-ubiquitin chain has been shown to stimulate the activity of USP5.

reach
Our finding suggests that the previous finding that ubiquitin (not C-terminal truncated) enhances the activity of USP5 37 is due to the binding of the beta-grasp domain of ubiquitin.

reach
It is known that occupancy of the S1 ' site by the proximal ubiquitin activates USP5 and that the C-terminal glycine (G76) of this ubiquitin is determinant for this activation XREF_BIBR XREF_BIBR.

reach
While submicromolar concentrations of ubiquitin activate isopeptidase T, higher concentrations are inhibitory.
USP5 affects TP53
| 17
USP5 inhibits TP53.
| 8
USP5 inhibits TP53. 8 / 9
| 8

reach
Suppression of the human USP5 gene also causes the accumulation of unanchored polyubiquitins and enhances the intracellular level of p53 [XREF_BIBR].

reach
Activation of p53 can be accounted for by the ability of USP5 suppression to inhibit the proteasomal degradation of p53 without affecting the degradation of Mdm2.

reach
Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53.

reach
Usp5 KD consistently led to p53 induction and accumulation of ubiquitinated p53 adducts while Usp5 overexpression diminished p53 content.

reach
XREF_BIBR, XREF_BIBR Further, Dayal et al reported that isopeptidase T inhibition causes both p53 activation and unanchored polyubiquitin chain accumulation.

reach
Previous study has shown that Usp5 knockdown promoted p53 activation, so we suppose that Usp5 may be involved in carcinogenesis.

reach
Similarly, the COPS2, COPS3, and USP5 which may degrade p53 were significantly upregulated in OCHA L compared to OTCS H (XREF_TABLE).

reach
Recently, it has been shown that Usp5 knockdown induces p53 activation [XREF_BIBR], and Usp5 controls activation of apoptotic signaling as well as Jun N-Terminal kinase pathway during eye development [XREF_BIBR].
USP5 activates TP53.
| 6
USP5 activates TP53. 6 / 8
| 6

reach
Knockdown of the mammalian IsoT (USP5) causes a similar accumulation of polyubiquitin as well as an increase in the proteasomal substrate p53 [XREF_BIBR].

reach
It has recently been shown that knock-down of the deubiquitinating enzyme USP5 (isopeptidaseT) causes p53 activation XREF_BIBR.

reach
Usp5 KD resulted in up-regulation of p53 in w/t p53 A375 cells and up-regulation of p73 in p53 mutant SK-Mel28 cells, suggesting that both proteins can be modulated by Usp5.

reach
Depletion of USP5 has been reported to cause accumulation of nuclear p53 and increase p53 transcriptional activity.

reach
Intriguingly, USP5 has been confirmed to mediate p53 signaling XREF_BIBR, wnt-beta-catenin pathway XREF_BIBR, Type I interferon signaling pathway XREF_BIBR, Notch and RTK signaling pathway XREF_BIBR.

reach
In previous study, p53 stabilization was mediated by Usp5 through accumulation of unanchored poly-ubiquitin chains which competed with p53 for entering into the proteasome [XREF_BIBR].
USP5 decreases the amount of TP53.
| 2
USP5 decreases the amount of TP53. 1 / 1
| 1

reach
Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.
Modified USP5 decreases the amount of TP53. 1 / 1
| 1

reach
Conversely, Usp5 overexpression suppressed the expression of p14 ARF and p53 and promoted Mdm2 expression, leading to inactivation of this signaling.
USP5 increases the amount of TP53.
| 1
USP5 increases the amount of TP53. 1 / 1
| 1

reach
We used Usp5 knockdown (KD), overexpression and enzyme inhibition to demonstrate that Usp5 suppresses p53 and FAS levels in melanoma and is associated with loss of checkpoint control and apoptotic sensitivity to kinase inhibitors and other agents.

reach
It has been reported that USP5 promotes tumor proliferation and tumorigenesis through the deubiquitination of histone deacetylase 2 (HDAC2) and beta-catenin.

reach
The siRNA induced knockdown of Usp5 inhibited cell proliferation, migration ability and drug resistance.

reach
Furthermore, the colony formation assays also showed that USP5 knockdown inhibited proliferation of PANC-1 and SW1990, two PDAC cell lines.To further evaluate the role of USP5 in PDAC progression, six[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]

reach
We concluded that USP5 promoted the proliferation of trophoblast cells via the up-regulation of the Wnt and beta-catenin signaling pathway.

reach
Taken together, these results suggested that USP5 could evidently promote pancreatic cancer cells proliferation and metastasis.

reach
23, 24, 25 NSCLC studies have shown that high expression levels of USP5 and USP7 in lung cancer tissue promote lung cancer cell proliferation by stabilizing beta-catenin.

reach
CCK-8 assay and colony formation experiments showed that overexpression of USP5 in Panc1 cells dramatically increased the proliferation.

reach
Our previous studies demonstrated that the deubiquitinase USP5 stabilizes c-Maf and promotes myeloma cell proliferation and survival; therefore, the USP5 and c-Maf axis could be a potential target for myeloma therapy.

reach
USP5 was recently found to stabilize c-Maf protein and promote myeloma cell proliferation and survival XREF_BIBR.

reach
Disruption of USP5 profoundly repressed cell proliferation by inducing cell cycle G0/G1 phase arrest in ovarian cancer cells.

sparser
The siRNA-induced knockdown of Usp5 inhibited cell proliferation, migration ability and drug resistance.
| 2 13
| 2 8

reach
Second, loss of usp5 activates apoptosis and the JNK pathway.

reach
Loss of usp5 activates apoptosis and the JNK pathway.

reach
USP5 knockdown leads to DNA damage, cell cycle arrest and apoptosis in PDAC cells.

eidos
USP5 deficiency also induces DNA damage , cell cycle arrest and apoptosis in pancreatic ductal adenocarcinoma cells ( 51 , 53 ) .

reach
Usp5 knockdown suppressed cell viability and induced apoptosis in HCC cells.

reach
Moreover, inhibiting USP5 by genetic shRNA or small molecule inhibitors such as WP1130 leads to MM cell apoptosis [XREF_BIBR].

eidos
In the present study , our objective is to study in broad the secondary down-stream effect after depleting USP5 or USP8 , which were initially showed to induce apoptosis in various cancers .

reach
Our study showed that Usp5 knockdown induced cell cycle arrest and apoptosis, at least partially associated with p53 expression.

reach
Moreover, inhibiting USP5 by genetic shRNA or small molecule inhibitors such as WP1130 leads to MM cell apoptosis [8].

reach
Therefore, usp5 suppression of apoptosis is necessary for the differentiation of photoreceptors.
USP5 activates apoptotic process.
| 5

reach
Further functional investigation also showed that Usp5 knockdown suppressed cell proliferation, migration, drug resistance and induced apoptosis; on the other hand, Usp5 overexpression promoted colony formation, migration, drug resistance and tumorigenesis.

reach
In the present study, our objective is to study in broad the secondary down-stream effect after depleting USP5 or USP8, which were initially showed to induce apoptosis in various cancers.

reach
In both w/t and mutant p53 expressing cells, Usp5 KD enhanced the onset or extent of apoptosis induced by vemurafenib, with evidence for activation of both the intrinsic and extrinsic pathway.

reach
USP5 deficiency also induces DNA damage, cell cycle arrest and apoptosis in pancreatic ductal adenocarcinoma cells.

reach
To focus on the mechanisms by which USP5 regulates eye development, we first wanted to know whether apoptosis is induced by the knock-out of usp5, since there is a possibility that interference with the differentiation process leads to apoptosis.
| 2 13
| 2 12

eidos
USP5 Promotes Metastasis in Non-Small Cell Lung Cancer by Inducing Epithelial-Mesenchymal Transition .

reach
USP5 Promotes Metastasis in Non Small Cell Lung Cancer by Inducing Epithelial-Mesenchymal Transition

reach
USP5 knockdown inhibits the progression and metastasis of pancreatic cancer.

eidos
USP5 Promotes Metastasis in Non-Small Cell Lung Cancer by Inducing Epithelial-Mesenchymal Transition via Wnt / beta-Catenin Pathway Ubiquitin-specific protease 5 ( USP5 ) is a deubiquitinating enzyme that functions as an oncoprotein in a variety of human cancers .

reach
USP5 Promotes Metastasis in Non Small Cell Lung Cancer by Inducing Epithelial-Mesenchymal Transition via Wnt and beta-Catenin Pathway.

reach
USP5 overexpression promotes the progression and metastasis of pancreatic cancer.

reach
USP5 promotes EMT and metastasis in hepatocellular carcinoma.

reach
Results elucidated that USP5 contribute to cell invasion and metastasis in pancreatic cancer.

reach
All the results indicated that USP5 promotes the growth and metastasis of hepatocellular carcinoma.

reach
Taken together, these results suggested that USP5 could evidently promote pancreatic cancer cells proliferation and metastasis.
| 1

reach
Moreover, USP5 intervention by shRNA knockdown has been reported to prevent the metastasis of hepatocellular carcinoma in vivo.
| 3 7

reach
In contrast with USP5 overexpression, knockdown USP5 inhibited cell invasion and migration.

reach
Meanwhile, USP5 was found to promote EMT, invasion, and migration of NSCLC cells, and its expression is correlated with EMT and metastasis in NSCLC tissues.

reach
Transwell assay and wound healing assay results also showed that knockdown of USP5 inhibited cell invasion and migration and overexpression of USP5 promoted cell invasion and migration.

eidos
Here , we found that USP5 resulted in an increase in E-cadherin expression and decreases in N-cadherin and vimentin expression , inhibiting invasion and migration in NSCLC cells .

eidos
It was suggested that USP5 promoted EMT , invasion , and migration in NSCLC cells .

reach
USP5 promotes EMT and the invasion and migration of NSCLC cells.

reach
Here, we found that USP5 resulted in an increase in E-cadherin expression and decreases in N-cadherin and vimentin expression, inhibiting invasion and migration in NSCLC cells.

reach
Results elucidated that USP5 contribute to cell invasion and metastasis in pancreatic cancer.

eidos
Meanwhile , USP5 was found to promote EMT , invasion , and migration of NSCLC cells , and its expression is correlated with EMT and metastasis in NSCLC tissues .

reach
It was suggested that USP5 promoted EMT, invasion, and migration in NSCLC cells.
USP5 is modified
| 1 9
USP5 is desumoylated.
| 9
USP5 is desumoylated. 9 / 9
| 9

sparser
AMSH, associated molecule with the SH3 domain of STAM; AMSHLP, AMSH-like protease; ATXN3, ataxin 3; BAP1, BRCA1-associated protein 1; CEZANNE, cellular zinc finger anti-NF-κB protein; CSN, COP9 signalosome complex subunit; CYLD, cylindromatosis; DESI, desumoylating isopeptidase; EIF3, eukaryotic translation initiation factor 3; JAMM, JAB1, MPN, MOV34 family; JOSD, josephin domain; MINDY, motif-interacting with ubiquitin-containing novel DUB family; MJD, Machado–Josephin domain-containing protease; OTUD, OTU domain-containing protein; PRPF8, pre-mRNA-processing splicing factor 8; UCHL, ubiquitin carboxy-terminal hydrolase-like; USP, ubiquitin-specific protease; VCPIP1, valosin-containing protein p97/p47 complex-interacting protein 1.

sparser
DeSUMOylating isopeptidase: a second class of SUMO protease.

sparser
Moreover, two additional SUMO isopeptidases have been described in humans, deSUMOylating isopeptidase (DeSI), and the ubiquitin-specific protease-like 1 (USPL1) ( xref ) [ xref ].

sparser
In addition to the SENP family, de-SUMOylating isopeptidase 1 and 2 (DeSI1 and 2) and ubiquitin-specific protease-like 1 (USPL1) can also function as SUMO-protease.

sparser
We acknowledge the caveat that a USP5 construct with a point mutation that prevents SUMOylation is not strictly equivalent to deSUMOylation of USP5.

sparser
Other SUMO proteases, such as Ubiquitin‐Specific Peptidase‐Like protein 1 xref , DeSumoylating Isopeptidase 1 and DeSumoylating Isopeptidase 2 xref , have been identified but do not appear to be involved in changing global SUMOylation patterns.

sparser
Recently, several additional SUMO proteases have been identified, DeSumoylating Isopeptidase 1 and 2 (DeSI1 and DeSI2; Shin et al., xref ) and USPL1 (Ubiquitin-Specific Protease-Like 1; Schulz et al., xref ).

sparser
Hence, preventing deSUMOylation of USP5 could provide a strategy for enhancing USP5 interactions with Cav3.2, which would in turn be predicted to lead to analgesia.

sparser
Members of the second family of SUMO proteases are desumoylating isopeptidase (DeSI) 1 and 2, which are primarily used for deconjugation of SUMO (reviewed in refs. xref , xref , xref ).
USP5 is deubiquitinated.
| 1
USP5 is deubiquitinated. 1 / 1
| 1

trips
Wnt signaling activation inhibits FoxM1 phosphorylation by GSK3-Axin complex and leads to interaction between FoxM1 and deubiquitinating enzyme USP5, thereby deubiquitination and stabilization of FoxM1.
USP5 affects STAT3
| 1 9
USP5 activates STAT3.
| 1 7
USP5 activates STAT3. 8 / 8
| 1 7

reach
USP5 mediates STAT3 signaling in pancreatic cancer.

reach
Inhibition of deubiquitinase USP5 suppresses STAT3 signaling and attenuates the inflammatory response of chronic periodontitis.

eidos
Suppressing USP5 inhibited STAT3 signaling in PDLSCs .

reach
In contrast, knockdown of USP5 suppressed the activation of STAT3.

reach
In this study, we confirmed that USP5 mediated STAT3 signaling.

reach
High USP5 expression promotes both progression and metastasis by activating STAT3 signaling.

reach
USP5 was also proved to mediate STAT3 signaling in pancreatic cancer cells.

reach
Suppressing USP5 inhibited STAT3 signaling in PDLSCs.
USP5 inhibits STAT3.
| 1
USP5 inhibits STAT3. 1 / 1
| 1

reach
Suppression deubiquitinase USP5 inhibits the inflammatory response of chronic periodontitis by suppressing STAT3 signaling.
USP5 decreases the amount of STAT3.
| 1
USP5 decreases the amount of STAT3. 1 / 1
| 1

reach
The DUB inhibitor described here reduced Usp9x and Usp5 activity, induced p53, FAS and NOXA, reduced pStat3 levels and amplified vemurafenib apoptotic activity in vitro.
USP5 affects SNAI2
| 10
USP5 activates SNAI2.
| 7
USP5 activates SNAI2. 7 / 7
| 7

reach
USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma.

reach
Consistently, USP5 overexpression prolonged the half-life of SLUG.

reach
Knockdown of USP5 inhibits SLUG deubiquitination and inhibits HCC cells proliferation, metastasis, and invasion, while overexpression of USP5 promotes SLUG stability and EMT in vitro and in vivo.

reach
In previous study, USP5 was found promoting EMT by stabilizing SLUG in hepatocellular carcinoma XREF_BIBR.

reach
USP5 targets the transcription factor SLUG and then induces EMT in hepatocellular carcinoma cells.

reach
ChIP analysis showed that knockdown of USP5 decreased the binding of SLUG to the promoter of E-cadherin.

reach
However, the importance of USP5 promoted SLUG stabilization in EMT must be examined.
USP5 inhibits SNAI2.
| 2
USP5 inhibits SNAI2. 2 / 2
| 2

reach
Luciferase reporter gene assay showed that knockdown USP5 interfered with the transcriptional inhibition of SLUG on E-cadherin, and over-expression of USP5 promoted the transcriptional inhibition of SLUG on E-cadherin.

reach
CHX and in vivo deubiquitination assay revealed that USP5 removed ubiquitin on SLUG and prevented SLUG from being ubiquitin degraded.
USP5 increases the amount of SNAI2.
| 1
Modified USP5 increases the amount of SNAI2. 1 / 1
| 1

reach
USP5 overexpression increased SLUG expression in PLC-PRF-5 and Hep3B cells.
USP5 affects MAF
| 3 5
USP5 activates MAF.
| 2 4
USP5 activates MAF. 6 / 6
| 2 4

reach
In the functional studies, USP5 was found to promoted the transcriptional activity of c-Maf.

eidos
In myeloma cells , USP5 stabilizes the c-Maf transcription factor , where inhibition of USP5 promotes c-Maf degradation and leads to apoptosis in myeloma cells [ 15 ] .

reach
In myeloma cells, USP5 stabilizes the c-Maf transcription factor, where inhibition of USP5 promotes c-Maf degradation and leads to apoptosis in myeloma cells [XREF_BIBR].

reach
Ectopic expression of USP5 significantly increased the transcriptional activity of c-Maf in terms of the measured luciferase activity.

eidos
In contrast , knockdown of USP5 leads to c-Maf degradation and MM cell apoptosis [ 8] .

reach
Notably, we found that USP5 mRNA expression was also decreased by mebendazole, suggesting that mebendazole might suppress USP5 transcription.Because c-Maf turnover is processed via the proteasome, we sought to determine whether mebendazole induced c-Maf Fig. 2 Mebendazole inhibits USP5 expression and induces c-Maf degradation via the ubiquitin-proteasome pathway.
USP5 inhibits MAF.
| 1 1
USP5 inhibits MAF. 2 / 2
| 1 1

reach
C-Maf ubiquitination can be reversed by the deubiquitinase USP5 because USP5 prevents c-Maf from polyubiquitination and degradation [8].

eidos
C-Maf ubiquitination can be reversed by the deubiquitinase USP5 because USP5 prevents c-Maf from polyubiquitination and degradation [ 8] .
USP5 affects Ubiquitin
| 1 6
| 1 6

reach
Isopeptidase T specifically degrades unanchored polyubiquitin chains by removing individual ubiquitin subunits in a step-wise fashion from the proximal end of the chain (Hadari et al., 1992).

reach
Thus, Leon and USP5 holds Ubqn in check and prevents ubiquitin homeostatic imbalance, making USP5 as a potential candidate disease gene in ubiquitin homeostasis related diseases.

sparser
Intriguingly, inhibition of ubiquitin by isopeptidase inhibitor (G5), which causes depletion of free nuclear ubiquitin [ xref ], prevented Top 1 degradation in CPT-treated T cells (4).

reach
Interestingly, although the RIG-I complex isolated from HEK293T cells contains both IsoT sensitive unanchored ubiquitin chains and IsoT resistant ubiquitin conjugates, the IsoT treatment completely abolished the ability of these ubiquitin chains to activate RIG-I (XREF_FIG), strongly suggesting that unanchored polyUb chains are responsible for RIG-I activation.

reach
We observed that both LRSAM1 and HRD1 displayed apparent autoubiquitination, and much of this signal was resistant to IsoT treatment, which degrades unanchored ubiquitin chains.

reach
In a cell study, USP5 and USP13 were found to degrade ubiquitin chains inside stress granules, defined as clumps of protein or RNA created when cells are stressed [XREF_BIBR].

reach
IsoT also reduced the pro-IL-1beta-associated ubiquitin (XREF_FIG, 4 th lane).
SMURF1 affects USP5
| 6
SMURF1 decreases the amount of USP5.
| 2
SMURF1 decreases the amount of USP5. 2 / 3
| 2

reach
Moreover, down-regulation of USP5 expression by Smurf1 was presented in a dose dependent manner.

reach
In this study, we identified the HECT-type E3 ligase, Smurf1, could regulate the stability and function of USP5.First of all, we demonstrated that USP5 protein levels could be reduced by Smurf1 in a d[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]
SMURF1 inhibits USP5.
| 3
SMURF1 inhibits USP5. 2 / 2
| 2

reach
Taken together, our results demonstrated that Smurf1 could promote USP5 degradation through increasing USP5 ubiquitination.Tumor necrosis factor alpha (TNF-alpha) is a central mediator of the inflamma[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]

reach
Because the ubiquitin ligase activity of Smurf1 was required for down-regulation of USP5 protein levels, we next sought to determine whether USP5 degradation mediated by Smurf1 is a consequence of ubi[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]
SMURF1 bound to USP5 inhibits USP5. 1 / 1
| 1

reach
Smurf1 interacted with USP5 and mediated the ubiquitination and proteasomal degradation of USP5.
SMURF1 increases the amount of USP5.
| 1
SMURF1 increases the amount of USP5. 1 / 1
| 1

reach
Moreover, down-regulation of USP5 expression by Smurf1 was presented in a dose dependent manner.
USP5 affects FOXM1
| 6
USP5 activates FOXM1.
| 2
USP5 activates FOXM1. 2 / 3
| 2

reach
USP5 promotes tumorigenesis and progression of pancreatic cancer by stabilizing FoxM1 protein.

reach
To investigate whether USP5 prolonged the half-life of FoxM1, we transfected PANC-1 cells with USP5 and measured FoxM1 expression level in the presence of the translational inhibitor CHX.
USP5 increases the amount of FOXM1.
| 2
USP5 increases the amount of FOXM1. 1 / 1
| 1

reach
As expected, knockdown of USP5 in PANC-1 cells decreased FoxM1 protein level but did not affect FoxM1 mRNA level.
Modified USP5 increases the amount of FOXM1. 1 / 1
| 1

reach
Overexpression of USP5 reduces the endogenous ubiquitination of FoxM1 and increases FoxM1 expression [25].
USP5 decreases the amount of FOXM1.
| 2
USP5 decreases the amount of FOXM1. 1 / 1
| 1

reach
Knockdown of USP5 in PANC-1 cells decreased FoxM1 protein level but did not affect FoxM1 mRNA level, indicating that FoxM1 was regulated at the post-transcriptional level.
Modified USP5 decreases the amount of FOXM1. 1 / 1
| 1

reach
Overexpression of USP5 reduces the endogenous ubiquitination of FoxM1 and increases FoxM1 expression [25].
USP5 affects cell cycle
| 1 5
USP5 activates cell cycle.
| 1 4
| 1 4

reach
USP5 deficiency also induces DNA damage, cell cycle arrest and apoptosis in pancreatic ductal adenocarcinoma cells.

reach
Disruption of USP5 profoundly repressed cell proliferation by inducing cell cycle G0/G1 phase arrest in ovarian cancer cells.

reach
It has identified NQQ1 as a potential drug target for host directed tuberculosis therapy, ATP1A1 as a gene that regulates aurilide B cytotoxicity, and the deubiquitinating enzyme, USP5, which modulates cell cycle regulators.34, 35, 36 The shRNA screening system has also identified HIF1alpha as a TERT regulator using mouse ES cells.37 In this study in a HCC cell line, we identified two genes, C15orf55 and C7orf43, as activators of TERT transcription through SP1 and YAP1, respectively.

eidos
USP5 deficiency also induces DNA damage , cell cycle arrest and apoptosis in pancreatic ductal adenocarcinoma cells ( 51 , 53 ) .

reach
It is noteworthy that USP5 is highly expressed in Gliomas [XREF_BIBR], where p53 stabilization effect caused due to the accumulation of unanchored polyubiquitin in the absence of USP5 causes cell cycle arrest [XREF_BIBR].
USP5 inhibits cell cycle.
| 1
| 1

reach
Our study showed that Usp5 knockdown induced cell cycle arrest and apoptosis, at least partially associated with p53 expression.
Formononetin affects USP5
| 5
Formononetin activates USP5.
| 3
| 3

reach
All the results showed that Formononetin directly targets USP5.

reach
To explore the influence of Formononetin on USP5 and SLUG axis, PLC-PRF-5 cells treated with Formononetin at different concentrations were used for WB analysis.

reach
In this study, we show that Formononetin directly targets USP5 and inhibits its deubiquitinase activity, thereby destabilizing SLUG and repressing EMT and HCC progression.
Formononetin inhibits USP5.
| 2
| 2

reach
Small molecules inhibitor WP1130 XREF_BIBR and Chinese medicine Formononetin XREF_BIBR were reported to inhibit USP5, which further indicated that targeting USP5 might be an effective strategy in pancreatic cancer treatment.

reach
To investigate the influence of Formononetin on inhibiting USP5, ChIP assay was conducted in cells treated with Formononetin at different concentrations.
USP5 affects IFNB1
| 3 2
USP5 inhibits IFNB1.
| 3
USP5 inhibits IFNB1. 3 / 3
| 3

eidos
In addition , a recent systematic functional screening assay revealed that USP5 inhibits IFNb expression and promotes VSV replication by recruiting STIP1 homology and Ubox containing protein 1 ( STUB1 ) to degrade RIG-I ( 40 ) .

eidos
Moreover , USP5 suppresses IFN-beta expression and enhances VSV replication by recruiting STUB1 to degrade RIG-I ( 40 ) .

eidos
Moreover , USP5 suppresses IFNb expression and enhances VSV replication by recruiting STUB1 to degrade RIG-I ( 40 ) .
USP5 decreases the amount of IFNB1.
| 1
USP5 decreases the amount of IFNB1. 1 / 1
| 1

reach
Moreover, USP5 suppresses IFN-β expression and enhances VSV replication by recruiting STUB1 to degrade RIG-I (40).
USP5 activates IFNB1.
| 1
USP5 activates IFNB1. 1 / 1
| 1

reach
In contrast, USP5 which shares 80% sequence similarity with USP13, neither interacted with STING in an overexpression system nor inhibited cGAS and STING induced activation of IFN-beta promoter in reporter assays (XREF_FIG), indicating a specific interaction between USP13 and STING.
USP5 affects Interferon
| 2 3
USP5 inhibits Interferon.
| 1 1
| 1 1

eidos
Type I IFN plays an important role in antiviral infection process , and USP5 can inhibit the production of type I IFN .

reach
Type I IFN plays an important role in antiviral infection process, and USP5 can inhibit the production of type I IFN.
USP5 increases the amount of Interferon.
| 1
USP5 increases the amount of Interferon. 1 / 1
| 1

reach
In summary, this study reveals that USP5 is able to activate higher levels of interferon by increasing RIG-I protein levels, and thus implement antivirus functions.
USP5 decreases the amount of Interferon.
| 1
USP5 decreases the amount of Interferon. 1 / 1
| 1

reach
In addition, a recent systematic functional screening assay revealed that USP5 inhibits IFNβ expression and promotes VSV replication by recruiting STIP1 homology and U-box containing protein 1 (STUB1) to degrade RIG-I (40).
USP5 activates Interferon.
| 1
| 1

eidos
In summary , this study reveals that USP5 is able to activate higher levels of interferon by increasing RIG-I protein levels , and thus implement antivirus functions .
USP5 affects DDX58
| 2 3
USP5 increases the amount of DDX58.
| 2
USP5 increases the amount of DDX58. 2 / 2
| 2

reach
USP5 was also able to enhance the expression of RIG-I and activate higher levels of IFNphi1 stimulated by Poly (I : C).

reach
In summary, this study reveals that USP5 is able to activate higher levels of interferon by increasing RIG-I protein levels, and thus implement antivirus functions.
USP5 inhibits DDX58.
| 1 1
USP5 inhibits DDX58. 1 / 1
| 1

eidos
IsoT somewhat reduces the MAVS stimulatory activity of RIG-I ( sample 2 ) , but is still more efficient than RIG-I without RIPLET ( sample 3 ) .
USP5 bound to STUB1 inhibits DDX58. 1 / 1
| 1

reach
A systematic functional screening revealed that USP5 can interact with and recruit STUB1 to mediate the degradation of RIG-I, thus enhancing VSV replication.
USP5 activates DDX58.
| 1
USP5 activates DDX58. 1 / 1
| 1

eidos
USP5 was also able to enhance the expression of RIG-I and activate higher levels of IFNphi1 stimulated by Poly ( I : C ) .
USP5 affects mebendazole
| 4
USP5 increases the amount of mebendazole. 4 / 4
| 4

reach
Notably, we found that USP5 mRNA expression was also decreased by mebendazole, suggesting that mebendazole might suppress USP5 transcription.

reach
The mechanistic investigation showed that mebendazole not only prevents the interaction between USP5 and c-Maf but also suppresses USP5 transcription, thus inducing c-Maf proteasomal degradation.

reach
The mechanistic investigation showed that mebendazole not only prevents the interaction between USP5 and c-Maf but also suppresses USP5 transcription, thus inducing c-Maf proteasomal degradation.Notably, mebendazole is cytotoxic to various cancer cells, including MM and leukemia cells, at higher concentrations (data not shown); however, it elicits selective anti-MM activity at low concentrations.

reach
Notably, we found that USP5 mRNA expression was also decreased by mebendazole, suggesting that mebendazole might suppress USP5 transcription.Because c-Maf turnover is processed via the proteasome, we sought to determine whether mebendazole induced c-Maf Fig. 2 Mebendazole inhibits USP5 expression and induces c-Maf degradation via the ubiquitin-proteasome pathway.
USP5 affects cell growth
| 4
USP5 activates cell growth.
| 3
| 3

reach
While USP5 knockdown effectively inhibited CRC cell growth, overexpressed USP5 promoted the growth of CRC cells and made them more resistant to doxorubicin (DOX).

reach
Usp5 overexpression promoted cell growth in vitro and stimulated tumorigenicity in vivo.

reach
In Pancreatic cancer, USP5 was shown to encourage oncogenicity by modulating the cell cycle regulators, as inhibition of USP5 attenuated pancreatic cell growth [XREF_BIBR].
USP5 inhibits cell growth.
| 1
| 1

reach
The forced expression of USP5 isoform 1 in two GBM cell lines inhibited cell growth and migration, implying an important role for USP5 splicing in gliomagenesis.
USP5 affects CDKN2A
| 4
USP5 inhibits CDKN2A.
| 3
USP5 inhibits CDKN2A. 3 / 3
| 3

reach
The P14 ARF -P53 signaling was activated by USP5 knockdown in HCC cells.

reach
Our results showed that the p14 ARF -p53 signaling was activated by Usp5 knockdown in HCC cells.

reach
Usp5 knockdown induced the activation of p14 ARF -p53 signaling in HCC cells.
USP5 decreases the amount of CDKN2A.
| 1
Modified USP5 decreases the amount of CDKN2A. 1 / 1
| 1

reach
Conversely, Usp5 overexpression suppressed the expression of p14 ARF and p53 and promoted Mdm2 expression, leading to inactivation of this signaling.
USP5 affects CACNA1H
| 4
USP5 increases the amount of CACNA1H.
| 2
USP5 increases the amount of CACNA1H. 2 / 2
| 2

reach
Knockdown of USP5 via shRNA or preventing its association with the channel by using Tat epitope fused disruptor peptides decreased Cav3.2 protein levels and produced analgesia in models of inflammatory and neuropathic pain in mice.

reach
Knockdown of USP5 via shRNA increases Cav3.2 ubiquitination, decreases Cav3.2 protein levels, and reduces Cav3.2 whole-cell currents.
USP5 activates CACNA1H.
| 2
USP5 activates CACNA1H. 2 / 2
| 2

reach
In the present study, we test the hypothesis that IL-1β activity can trigger USP5-mediated Cav3.2 channel plasticity to induce pain.

reach
The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity.
SNAP25 affects USP5
| 4
SNAP25 inhibits USP5.
| 3
SNAP25 inhibits USP5. 3 / 3
| 3

reach
A kinetics assay showed that isopeptidase T activity plateaued after 60 minutes, and SNAP concentrations above 250 mumol/L significantly inhibited isopeptidase T activity (XREF_FIG).

reach
Increasing concentrations of SNAP led to significantly increased inhibition of isopeptidase T activity (P <.001 at SNAP> = 500 mumol/L) (XREF_FIG).

reach
DTT significantly prevented SNAP mediated inhibition of isopeptidase T activity, restoring activity to 77.8% of control (* P <.001 vs control; ** P <.001 vs SNAP) (XREF_FIG).
SNAP25 activates USP5.
| 1
SNAP25 activates USP5. 1 / 1
| 1

reach
GSH significantly prevented inhibition of isopeptidase T activity mediated by SNAP, with activity levels observed at 77.8% of control (* P <.001 vs control; ** P <.001 vs SNAP) (XREF_FIG).
USP5 affects FAS
| 4
USP5 decreases the amount of FAS.
| 2
USP5 decreases the amount of FAS. 2 / 2
| 2

reach
Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.

reach
We used Usp5 knockdown (KD), overexpression and enzyme inhibition to demonstrate that Usp5 suppresses p53 and FAS levels in melanoma and is associated with loss of checkpoint control and apoptotic sensitivity to kinase inhibitors and other agents.
USP5 inhibits FAS.
| 1
USP5 inhibits FAS. 1 / 1
| 1

reach
FAS reduction by Usp5 appears to be mediated at the transcriptional level, possibly through down-regulation of p53 and other factors (XREF_SUPPLEMENTARY).
USP5 increases the amount of FAS.
| 1
USP5 increases the amount of FAS. 1 / 1
| 1

reach
In melanoma cells, USP5 has been reported to modulate FAS expression in a p53 dependent manner, thereby controlling growth [XREF_BIBR].
Glutathione affects USP5
| 3
| 3

reach
GSH significantly prevented inhibition of isopeptidase T activity mediated by SNAP, with activity levels observed at 77.8% of control (* P <.001 vs control; ** P <.001 vs SNAP) (XREF_FIG).

reach
Dithiothreitol and glutathione (5 mmol/L) both significantly reversed NO mediated inhibition of isopeptidase T activity (P <.001).

reach
Dithiothreitol and glutathione prevent the inhibition of isopeptidase T activity by NO.
USP5 affects Pain
| 3
USP5 activates Pain. 3 / 3
| 3

reach
This neuronal-activity-induced USP5 upregulation may underlie a protective, transient sensitization of the pain pathway.

reach
The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity.

reach
We showed that depletion of USP5, or its uncoupling from Cav3.2 channels via delivery of Tat peptides prevented and/or reversed the pain phenotype in models of peripheral inflammation (i.e., formalin and CFA) and peripheral nerve injury (i.e., partial sciatic nerve ligation).
BRAF affects USP5
| 1 2
BRAF activates USP5. 3 / 3
| 1 2

sparser
Overall, our results demonstrate that BRAF activates Usp5 to suppress cell cycle checkpoint control and apoptosis by blocking p53 and FAS induction; all of which can be restored by small molecule-mediated Usp5 inhibition.

reach
Usp5 was consistently suppressed, but not fully inhibited, by kinase inhibitor or BRAF knockdown.

reach
Overall, our results demonstrate that BRAF activates Usp5 to suppress cell cycle checkpoint control and apoptosis by blocking p53 and FAS induction; all of which can be restored by small molecule mediated Usp5 inhibition.
Vemurafenib affects USP5
| 3
Vemurafenib activates USP5.
| 2
| 2

reach
To determine whether BRAF mediated-DUB activation regulates the cellular response to vemurafenib, control and Usp5 KD cells were treated with vemurafenib for the interval indicated.

reach
To determine whether Usp5 KD (or G9) could overcome vemurafenib resistance, Usp5 KD A375R cells were left untreated or treated with vemurafenib (for 24 hrs) before assessing caspase activation, PARP and Bid cleavage.
Vemurafenib inhibits USP5.
| 1
| 1

reach
We compared DUB activity in vemurafenib and G9 treated cells and show that vemurafenib suppressed Usp5 activity in sensitive but not resistance cells, although pERK was reduced by kinase inhibitor in either cell type.
Doxycycline affects USP5
| 3
Doxycycline inhibits USP5.
| 2
| 2

reach
H2A.X in Western blot analyses in response to doxycycline induced USP5 knockdown.

reach
Cells were cultured for eleven days using the liquid overlay technique in the presence or absence of doxycycline to induce USP5 knockdown and cell viability repeatedly assessed by chemiluminescence assays.
Doxycycline activates USP5.
| 1
| 1

reach
Intriguingly, the cell cycle regulator p21 was also strongly and reproducibly upregulated in response to transient siRNA mediated USP5 knockdown, but this effect was reversed in stably transfected clones in which USP5 downregulation was mediated by doxycycline inducible shRNA constructs.
USP5 affects TNF
| 3
USP5 activates TNF.
| 2
USP5 activates TNF. 2 / 2
| 2

reach
Because inhibition of TNF-alpha production in RBL-2H3 cells treated with USP5 siRNA1 and USP5 siRNA2 was observed (XREF_FIG), we examined the effect of USP5 siRNA1 and USP5 siRNA2 on TNF-alpha mRNA expression.

reach
Taken together, our study for the first time clarified that the E3 ligase Smurf1 regulates USP5 protein stability and USP5 mediated TNF-alpha production through the ubiquitin proteasome pathway.
USP5 increases the amount of TNF.
| 1
USP5 increases the amount of TNF. 1 / 1
| 1

reach
USP5, a stress granule protein, increases TNFα expression through the ubiquitin-proteasome pathway and regulates inflammatory response through Smurf1.
| PMC
USP5 affects Notch
| 3
USP5 inhibits Notch.
| 2
USP5 inhibits Notch. 2 / 2
| 2

reach
Loss of Usp5 results in upregulation of Notch signaling and downregulation of RTK signaling, leading to impaired photoreceptor development.

reach
The loss of the deubiquitinating protein Ubiquitin carboxyl-terminal hydrolase 5 (Usp5) leads to the upregulation of Notch during Drosophila melanogaster eye development [XREF_BIBR].
USP5 activates Notch.
| 1
USP5 activates Notch. 1 / 1
| 1

reach
Intriguingly, USP5 has been confirmed to mediate p53 signaling XREF_BIBR, wnt-beta-catenin pathway XREF_BIBR, Type I interferon signaling pathway XREF_BIBR, Notch and RTK signaling pathway XREF_BIBR.
USP5 affects IFNB
| 1 2
USP5 decreases the amount of IFNB.
| 2
USP5 decreases the amount of IFNB. 2 / 2
| 2

reach
Moreover, USP5 suppresses IFNb expression and enhances VSV replication by recruiting STUB1 to degrade RIG-I (40) .

reach
In addition, a recent systematic functional screening assay revealed that USP5 inhibits IFNb expression and promotes VSV replication by recruiting STIP1 homology and Ubox containing protein 1 (STUB1) to degrade RIG-I (40) .
USP5 inhibits IFNB.
| 1
USP5 inhibits IFNB. 1 / 1
| 1

eidos
In addition , a recent systematic functional screening assay revealed that USP5 inhibits IFNbeta expression and promotes VSV replication by recruiting STIP1 homology and U-box containing protein 1 ( STUB1 ) to degrade RIG-I ( 40 ) .
USP5 affects ELAVL1
| 1 2
USP5 inhibits ELAVL1.
| 1 1
USP5 inhibits ELAVL1. 2 / 2
| 1 1

eidos
MAFG-AS1 direct binding to HuR could recruit USP5 to prevent HuR from degrading by ubiquitination ; BUC patients with high levels of MAFG-AS1 have poor prognosis ; lncRNA MAFG-AS1 is correlated with aggressive characteristics of BUC ; Cell transfection Plasmids for overexpression MAFG-AS1 were purchased from GeneChem Biotechnology ( Shanghai , China ) .
| PMC

reach
Mechanistically, MAFG-AS1 direct binding to Hu antigen R (HuR) could recruit ubiquitin specific proteinase 5 (USP5) to prevent HuR from degrading by ubiquitination.
| PMC
USP5 increases the amount of ELAVL1.
| 1
USP5 increases the amount of ELAVL1. 1 / 1
| 1

reach
Among the selected enzymes, knockdown of USP5 repressed the protein level of HuR the most.
| PMC
USP5 affects CAV3
| 3
USP5 decreases the amount of CAV3.
| 2
USP5 decreases the amount of CAV3. 2 / 2
| 2

reach
Knockdown of USP5 via shRNA or preventing its association with the channel by using Tat epitope fused disruptor peptides decreased Cav3.2 protein levels and produced analgesia in models of inflammatory and neuropathic pain in mice.

reach
Knockdown of USP5 via shRNA increases Cav3.2 ubiquitination, decreases Cav3.2 protein levels, and reduces Cav3.2 whole-cell currents.
USP5 activates CAV3.
| 1
USP5 activates CAV3. 1 / 1
| 1

reach
Furthermore, it is revealed recently that USP5 is able to modulate neuropathic and inflammatory pain by enhancing Cav3.2 channel activity [8,9].
USP5 affects CTNNB1
| 1 2
USP5 inhibits CTNNB1.
| 1
USP5 inhibits CTNNB1. 1 / 1
| 1

eidos
Taken together , these findings indicated that USP5 prevented beta-catenin degradation by inhibiting its ubiquitination and regulated the Wnt / beta-catenin signaling pathway to promote EMT in NSCLC cells .
USP5 increases the amount of CTNNB1.
| 1
USP5 increases the amount of CTNNB1. 1 / 1
| 1

reach
In the experiments of overexpression, USP5 promoted the proliferation of trophoblast cells, and up-regulated the expressions of beta-catenin and the downstream signals c-Myc and Cyclin D1 in trophoblast cells.
USP5 activates CTNNB1.
| 1
USP5 activates CTNNB1. 1 / 1
| 1

reach
23, 24, 25 NSCLC studies have shown that high expression levels of USP5 and USP7 in lung cancer tissue promote lung cancer cell proliferation by stabilizing beta-catenin.
| 2

sparser
Moreover, inhibiting USP5 by genetic shRNA or small molecule inhibitors such as WP1130 leads to MM cell apoptosis [8] .

sparser
Moreover, inhibiting USP5 by genetic shRNA or small molecule inhibitors such as WP1130 leads to MM cell apoptosis [ xref ].
Hsa-miR-3919 affects USP5
2 |